Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 21.0
(-0.43%)
CNY 21.0
(-0.43%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 108.34 Million CNY | 101.98% |
| 2022 | 53.64 Million CNY | 784.67% |
| 2021 | 6.06 Million CNY | -91.52% |
| 2020 | 71.49 Million CNY | 1329.85% |
| 2019 | 5 Million CNY | -57.26% |
| 2018 | 11.7 Million CNY | 485.0% |
| 2017 | 2 Million CNY | -80.0% |
| 2016 | 10 Million CNY | -6.54% |
| 2015 | 10.7 Million CNY | -55.04% |
| 2014 | 23.79 Million CNY | 28.23% |
| 2013 | 18.55 Million CNY | 9164.01% |
| 2012 | 200.34 Thousand CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 5 Million CNY | -92.84% |
| 2024 Q2 | 108.19 Million CNY | 95.61% |
| 2024 Q1 | 55.31 Million CNY | -48.95% |
| 2023 Q3 | 52.92 Million CNY | 1.72% |
| 2023 Q4 | 108.34 Million CNY | 104.73% |
| 2023 FY | 108.34 Million CNY | 101.98% |
| 2023 Q1 | 53.12 Million CNY | -0.96% |
| 2023 Q2 | 52.02 Million CNY | -2.07% |
| 2022 Q4 | 53.64 Million CNY | -5.89% |
| 2022 Q1 | 6 Million CNY | -0.91% |
| 2022 Q2 | 57.37 Million CNY | 854.97% |
| 2022 FY | 53.64 Million CNY | 784.67% |
| 2022 Q3 | 56.99 Million CNY | -0.66% |
| 2021 Q3 | 3.05 Million CNY | -10.45% |
| 2021 FY | 6.06 Million CNY | -91.52% |
| 2021 Q1 | - CNY | 0.0% |
| 2021 Q2 | 3.41 Million CNY | 0.0% |
| 2021 Q4 | 6.06 Million CNY | 98.53% |
| 2020 Q3 | 19.8 Million CNY | -55.8% |
| 2020 FY | 71.49 Million CNY | 1329.85% |
| 2020 Q2 | 44.8 Million CNY | -10.04% |
| 2020 Q1 | 49.8 Million CNY | 896.0% |
| 2020 Q4 | - CNY | -100.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2019 Q3 | - CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q4 | 5 Million CNY | 0.0% |
| 2019 FY | 5 Million CNY | -57.26% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 FY | 11.7 Million CNY | 485.0% |
| 2018 Q4 | 11.7 Million CNY | -71.18% |
| 2018 Q2 | 10 Million CNY | 0.0% |
| 2018 Q3 | 40.6 Million CNY | 306.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q3 | 10 Million CNY | -16.67% |
| 2017 Q4 | 2 Million CNY | -80.0% |
| 2017 FY | 2 Million CNY | -80.0% |
| 2017 Q2 | 12 Million CNY | 0.0% |
| 2016 FY | 10 Million CNY | -6.54% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 10 Million CNY | 0.0% |
| 2015 Q4 | 10.7 Million CNY | 0.0% |
| 2015 FY | 10.7 Million CNY | -55.04% |
| 2015 Q2 | 10.1 Million CNY | -5.61% |
| 2015 Q1 | 10.7 Million CNY | 0.0% |
| 2014 FY | 23.79 Million CNY | 28.23% |
| 2013 FY | 18.55 Million CNY | 9164.01% |
| 2012 FY | 200.34 Thousand CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 97.475% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.34 Billion CNY | 96.762% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | 84.828% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 90.459% |
| Medicalsystem Biotechnology Co., Ltd. | 108.17 Million CNY | -0.162% |
| Maccura Biotechnology Co.Ltd | 665.16 Million CNY | 83.711% |
| Guangzhou Wondfo Biotech Co.,Ltd | 599.53 Million CNY | 81.928% |
| Guangdong Hybribio Biotech Co.,Ltd. | 56.65 Million CNY | -91.247% |
| BGI Genomics Co., Ltd. | 1.09 Billion CNY | 90.118% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | 71.079% |